Furthermore, treatment of NSCLC cells and LC PDOs with TAT-1/6i reduced arginine methylation of ILF2 (Figure 6F) indicating that PRMT1/PRMT6 heteromer is responsible for ILF2 methylation. The gene discussed is PRMT1; the disease is non-small cell lung carcinoma.